|
시장보고서
상품코드
1812408
세포 면역요법 시장 : 요법 유형별, 유래별, 적응증별, 제조 모달리티별, 최종사용자별, 지역별Cellular Immunotherapy Market, By Therapy Type, By Source, By Indication, By Manufacturing Modality, By End User, By Geography |
||||||
세포 면역요법 시장은 2025년에는 76억 4,000만 달러로 추정되며, 2032년에는 204억 5,000만 달러에 달할 전망이며, 2025년부터 2032년까지 CAGR로 15.1%의 성장이 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 2025년 시장 규모 | 76억 4,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2020-2024년 |
| 예측 기간 : 2025-2032년 CAGR | 15.10% | 2032년 가치 예측 | 204억 5,000만 달러 |
세포 면역요법 세계 시장은 현대 의학의 혁명적인 패러다임 전환을 상징하는 것으로, 체내 면역체계를 활용하여 다양한 질병, 특히 암과 자가면역질환을 퇴치하는 것입니다.
이 혁신적인 치료법은 면역세포를 추출, 수정하여 다시 환자에게 되돌려줌으로써 자연 방어 메커니즘을 강화하는 혁신적인 치료법입니다. 세포 면역요법에는 CAR-T 세포 치료, 종양침윤림프구(TIL) 치료, 자연살해(NK) 세포 치료, 수지상세포 백신 등 다양한 치료법이 있으며, 각 치료법은 특정 질병 경로를 표적으로 하는 고유한 작용기전을 가지고 있습니다.
난치성 혈액암 치료에 탁월한 효과를 보인 Kymriah와 Yescarta와 같은 CAR-T 치료제의 획기적인 승인으로 시장은 전례 없는 성장세를 보이고 있습니다. 자동 세포 처리 시스템, 폐쇄형 바이오리액터와 같은 첨단 제조 기술은 이러한 맞춤형 치료의 확장성과 표준화를 크게 향상시켰습니다.
CRISPR-Cas9과 같은 유전자 편집 도구, 합성생물학 플랫폼, 인공지능을 활용한 환자 선택 알고리즘 등 생명공학 혁신의 융합은 세포 면역요법의 치료 가능성을 계속 확장하고 있습니다. 전 세계적으로 의료 시스템이 이러한 생물의약품의 혁신 가능성을 인식함에 따라 연구 인프라, 규제 프레임워크, 상환 정책에 대한 막대한 투자가 이루어지고 있으며, 다양한 환자군에 대한 시장 진입과 접근성을 가속화하고 있습니다.
시장 역학
세계 세포 면역요법 시장은 몇 가지 매력적인 요인에 의해 강력한 성장세를 보이고 있으며, 그 주요 요인은 전 세계 암 발병률의 증가, 특히 세포 면역요법가 탁월한 임상적 성과를 보이고 있는 혈액악성종양입니다. 이 시장은 제약사, 바이오기업, 학계의 연구개발 활동에 대한 막대한 투자로 차세대 세포공학 기술의 혁신이 촉진되고, 치료 응용이 종양학뿐만 아니라 자가면역질환, 감염질환, 재생의료까지 확대되고 있어 큰 수혜를 받고 있습니다.
세포 면역요법에 대한 규제 당국의 신속 승인 경로, 혁신치료제 지정, 희귀질환 치료제 지정은 유망한 치료제의 시장 출시 시간을 단축하고 지속적인 투자와 개발을 촉진하고 있습니다.
그러나 맞춤형 세포 가공에 따른 높은 제조 비용, 전문 시설과 숙련된 인력을 필요로 하는 복잡한 공급망 물류, 제품의 품질과 일관성을 유지하면서 생산 규모를 확대하기 위한 기술적 과제 등 시장은 큰 제약요인에 직면해 있습니다. 환자별 치료제를 제조하는 데 몇 주가 소요되는 긴 제조 기간은 경영상의 문제를 야기하고 중증 환자들의 치료 접근성을 제한하고 있습니다.
또한, 특정 세포 면역요법과 관련된 사이토카인 방출 증후군, 신경독성 등 심각한 부작용은 전문적인 의료 인프라와 전문 지식이 필요하기 때문에 자원이 충분하지 않은 의료 시설에서 채택을 제한할 수 있습니다. 이러한 어려움에도 불구하고, 이 시장은 현재 혈액학적 적응증보다 환자 수가 훨씬 많은 고형암에 대한 적응증 확대와 비용과 제조의 복잡성을 획기적으로 줄이고 세계 시장에서 치료 접근성과 확장성을 향상시킬 수 있는 기성품 동종세포 치료제 개발을 통해 큰 큰 비즈니스 기회를 가져오고 있습니다.
본 조사의 주요 특징
- 세계의 세포 면역요법 시장을 상세히 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년)의 시장 규모(10억 달러)와 연평균 성장률(CAGR)을 조사하여 전해드립니다.
- 또한, 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
- 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 세포 면역요법 시장의 주요 기업을 프로파일링합니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 세포 면역요법 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 세포 면역요법 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 가정
- 조사 목적
- 가정
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 발매/승인
- PEST 분석
- PORTER의 분석
- 인수합병 시나리오
- 업계 동향
제4장 세계의 세포 면역요법 시장, 요법 유형별, 2020-2032년
- CAR T 세포 치료(키메라 항원 수용체 T 세포 치료)
- TCR-T 세포 치료(T세포 수용체 T 세포 치료)
- NK 세포 치료(자연살해세포 요법)
- 수지상세포 요법
- 종양침윤림프구(TIL) 요법
- 대식세포를 이용한 세포 치료
- 기타(신흥/신규 세포 유형)
제5장 세계의 세포 면역요법 시장, 유래별, 2020-2032년
- 자가 세포(환자 유래 세포)
- 동종 세포(기증 유래 세포)
제6장 세계의 세포 면역요법 시장, 적응증별, 2020-2032년
- 암
- 조혈 악성 종양(예 : 백혈병, 림프종, 골수종)
- 감염증
- 바이러스 감염증(예 : HIV, HBV, HCV, COVID-19)
- 자가면역질환
- 다발성 경화증
- 기타
제7장 세계의 세포 면역요법 시장, 제조 모달리티별, 2020-2032년
- Ex Vivo 세포 증식
- In Vivo 엔지니어링
제8장 세계의 세포 면역요법 시장, 최종사용자별, 2020-2032년
- 병원과 진료소
- 전문 내분비·비만 센터
- 외래 수술 센터(ASC)
- 재택의료 서비스
- 기타(학술·연구기관 등)
제9장 세계의 세포 면역요법 시장, 지역별, 2020-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 남아프리카공화국
- 북아프리카
- 중앙아프리카
제10장 경쟁 구도
- Novartis AG
- Gilead Sciences Inc(Kite Pharma)
- Bristol Myers Squibb Company
- Johnson and Johnson(Janssen Biotech)
- Cellectis S.A.
- Adaptimmune Therapeutics plc
- Autolus Therapeutics plc
- Allogene Therapeutics Inc
- Atara Biotherapeutics Inc
- Legend Biotech Corporation
- bluebird bio Inc
- Fate Therapeutics Inc
- ImmunityBio Inc
- Iovance Biotherapeutics Inc
- Poseida Therapeutics Inc
제11장 애널리스트의 추천사항
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제12장 참고문헌과 조사 방법
- 참고문헌
- 조사 방법
- 출판사 소개
Cellular Immunotherapy Market is estimated to be valued at USD 7.64 Bn in 2025 and is expected to reach USD 20.45 Bn by 2032, growing at a compound annual growth rate (CAGR) of 15.1% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 7.64 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 15.10% | 2032 Value Projection: | USD 20.45 Bn |
The global cellular immunotherapy market represents a revolutionary paradigm shift in modern medicine, leveraging the body's own immune system to combat various diseases, particularly cancer and autoimmune disorders.
This innovative therapeutic approach involves extracting, modifying, and reintroducing immune cells back into patients to enhance their natural defense mechanisms. Cellular immunotherapy encompasses diverse treatment modalities including CAR-T cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, natural killer (NK) cell therapy, and dendritic cell vaccines, each offering unique mechanisms of action to target specific disease pathways.
The market has witnessed unprecedented growth following breakthrough approvals of CAR-T therapies such as Kymriah and Yescarta, which demonstrated remarkable efficacy in treating refractory hematologic malignancies. Advanced manufacturing technologies, including automated cell processing systems and closed-system bioreactors, have significantly improved the scalability and standardization of these personalized treatments.
The convergence of biotechnology innovations, including gene editing tools like CRISPR-Cas9, synthetic biology platforms, and artificial intelligence-driven patient selection algorithms, continues to expand the therapeutic potential of cellular immunotherapies. As healthcare systems globally recognize the transformative potential of these living medicines, substantial investments in research infrastructure, regulatory frameworks, and reimbursement policies are accelerating market adoption and accessibility across diverse patient populations.
Market Dynamics
The global cellular immunotherapy market experiences robust growth driven by several compelling factors, with the primary driver being the increasing prevalence of cancer worldwide, particularly hematologic malignancies where cellular immunotherapies have demonstrated exceptional clinical outcomes. The market benefits significantly from substantial investments in research and development activities by pharmaceutical giants, biotechnology companies, and academic institutions, fostering innovation in next-generation cell engineering technologies and expanding therapeutic applications beyond oncology into autoimmune diseases, infectious diseases, and regenerative medicine.
Regulatory agencies' establishment of expedited approval pathways, breakthrough therapy designations, and orphan drug status for cellular immunotherapies has accelerated time-to-market for promising treatments, encouraging continued investment and development.
However, the market faces considerable restraints including extremely high manufacturing costs associated with personalized cell processing, complex supply chain logistics requiring specialized facilities and trained personnel, and significant technical challenges in scaling production while maintaining product quality and consistency. Lengthy manufacturing timelines, often requiring weeks to produce patient-specific treatments, pose additional operational challenges and limit treatment accessibility for critically ill patients.
Furthermore, severe adverse events such as cytokine release syndrome and neurotoxicity associated with certain cellular immunotherapies necessitate specialized medical infrastructure and expertise, constraining adoption in healthcare facilities lacking adequate resources. Despite these challenges, the market presents substantial opportunities through expanding applications into solid tumors, which represent a significantly larger patient population than current hematologic indications, and the development of off-the-shelf allogeneic cell therapies that could dramatically reduce costs and manufacturing complexity while improving treatment accessibility and scalability across global markets.
Key Features of the Study
- This report provides in-depth analysis of the global cellular immunotherapy market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global cellular immunotherapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis AG, Gilead Sciences Inc (Kite Pharma), Bristol Myers Squibb Company, Johnson and Johnson (Janssen Biotech), Cellectis S.A., Adaptimmune Therapeutics plc, Autolus Therapeutics plc, Allogene Therapeutics Inc, Atara Biotherapeutics Inc, Legend Biotech Corporation, bluebird bio Inc, Fate Therapeutics Inc, ImmunityBio Inc, Iovance Biotherapeutics Inc, and Poseida Therapeutics Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global cellular immunotherapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cellular immunotherapy market
Market Segmentation
- Therapy Type Insights (Revenue, USD Bn, 2020 - 2032)
- CAR T-Cell Therapy (Chimeric Antigen Receptor T-cell)
- TCR-T Cell Therapy (T-Cell Receptor T-cell)
- NK Cell Therapy (Natural Killer cell therapy)
- Dendritic Cell Therapy
- Tumor-Infiltrating Lymphocytes (TIL) Therapy
- Macrophage-Based Cell Therapy
- Others (emerging/novel cell types)
- Source Insights (Revenue, USD Bn, 2020 - 2032)
- Autologous (patient-derived cells)
- Allogeneic (donor-derived cells)
- Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Cancer
- Hematologic Malignancies (e.g., leukemia, lymphoma, myeloma)
- Solid Tumors (e.g., lung, breast, melanoma, ovarian, glioblastoma)
- Infectious Diseases
- Viral Infections (e.g., HIV, HBV, HCV, COVID-19)
- Bacterial Infections (e.g., tuberculosis)
- Autoimmune Disorders
- Multiple Sclerosis
- Rheumatoid Arthritis
- Type 1 Diabetes
- Others
- Manufacturing Modality Insights (Revenue, USD Bn, 2020 - 2032)
- Ex Vivo Cell Expansion
- In Vivo Engineering
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals and Clinics
- Specialty Endocrinology and Obesity Centers
- Ambulatory Surgical Centers (ASCs)
- Home Healthcare Services
- Others (Academic and Research Institutes, etc.)
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novartis AG
- Gilead Sciences Inc (Kite Pharma)
- Bristol Myers Squibb Company
- Johnson and Johnson (Janssen Biotech)
- Cellectis S.A.
- Adaptimmune Therapeutics plc
- Autolus Therapeutics plc
- Allogene Therapeutics Inc
- Atara Biotherapeutics Inc
- Legend Biotech Corporation
- bluebird bio Inc
- Fate Therapeutics Inc
- ImmunityBio Inc
- Iovance Biotherapeutics Inc
- Poseida Therapeutics Inc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Cellular Immunotherapy Market, By Therapy Type
- Global Cellular Immunotherapy Market, By Source
- Global Cellular Immunotherapy Market, By Indication
- Global Cellular Immunotherapy Market, By Manufacturing Modality
- Global Cellular Immunotherapy Market, By End User
- Global Cellular Immunotherapy Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Cellular Immunotherapy Market, By Therapy Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- CAR T-Cell Therapy (Chimeric Antigen Receptor T-cell)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- TCR-T Cell Therapy (T-Cell Receptor T-cell)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- NK Cell Therapy (Natural Killer cell therapy)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Dendritic Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Tumor-Infiltrating Lymphocytes (TIL) Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Macrophage-Based Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (emerging/novel cell types)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Cellular Immunotherapy Market, By Source, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Autologous (patient-derived cells)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Allogeneic (donor-derived cells)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Cellular Immunotherapy Market, By Indication, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hematologic Malignancies (e.g., leukemia, lymphoma, myeloma)
- Solid Tumors (e.g., lung, breast, melanoma, ovarian, glioblastoma)
- Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Viral Infections (e.g., HIV, HBV, HCV, COVID-19)
- Bacterial Infections (e.g., tuberculosis)
- Autoimmune Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Multiple Sclerosis
- Rheumatoid Arthritis
- Type 1 Diabetes
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Cellular Immunotherapy Market, By Manufacturing Modality, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Ex Vivo Cell Expansion
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- In Vivo Engineering
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Cellular Immunotherapy Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty Endocrinology and Obesity Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ambulatory Surgical Centers (ASCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Home Healthcare Services
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (Academic and Research Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Cellular Immunotherapy Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive landscape
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences Inc (Kite Pharma)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson and Johnson (Janssen Biotech)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cellectis S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Adaptimmune Therapeutics plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Autolus Therapeutics plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allogene Therapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Atara Biotherapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Legend Biotech Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- bluebird bio Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Fate Therapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ImmunityBio Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Iovance Biotherapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Poseida Therapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
